In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on ENDRA Life Sciences (NDRA – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $0.22.
According to TipRanks, Bernardino is a 5-star analyst with an average return of 19.7% and a 32.72% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Phio Pharmaceuticals, Gamida Cell, and Geron.
ENDRA Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on ENDRA Life Sciences’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.59 million. In comparison, last year the company had a GAAP net loss of $3.2 million
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NDRA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.
Read More on NDRA:
